Riskpilot← Back to searchSign inGet full accessBioimics AB
ABIn liquidationOrg 5566092507Other research and experimental development on natural sciences and engineering · NACE 7219Est. 20012 employees
Revenue 2021
SEK 245K
+18% vs 2020
EBITDA margin
-1142.0%
+41% vs 2020
Equity ratio
35.1%
Financial strength
Net profit 2021
SEK -2,8M
+41% vs 2020
| Revenue | SEK 245K | +18% |
| EBITDA | SEK -2,8M | +41% |
| Net profit | SEK -2,8M | +41% |
| Total assets | SEK 555K | +90% |
| Equity | SEK 195K | +134% |
| Employees | 2 | — |
Legal name
Bioimics AB
Org number
5566092507
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
31 mars 2001
Share capital
SEK 4 469 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Föremålet för bolagets verksamhet är att bedriva utveckling och kommersialisering av läkemedel, metoder för läkemedelsutveckling, diagnostiska metoder inom sjukvårdsområdet samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 56 | 0 | 0 | 207 | 245 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −6 876 | −3 736 | −3 988 | −4 721 | −2 798 |
| Depreciation & amort. | −11 | −11 | −10 | −0 | −0 |
| EBIT | −6 887 | −3 747 | −3 998 | −4 721 | −2 798 |
| Net financials | −98 | — | — | 1 | — |
| Profit before tax | −6 986 | −3 747 | −3 998 | −4 722 | −2 799 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −6 986 | −3 747 | −3 998 | −4 722 | −2 799 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 1 703 | 1 597 | 4 504 | 292 | 555 |
| Equity | 874 | 1 135 | 4 141 | −580 | 195 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 829 | 462 | 362 | 872 | 360 |
| Total debt | 829 | 462 | 362 | 872 | 360 |
EBITDA margin
-1142.0%
This company
15.8%
Market median
-7328% vs market
20172021
Equity ratio
35.1%
This company
38.2%
Market median
+8% vs market
20172021
Return on equity
-1435.4%
This company
18.4%
Market median
-7901% vs market
20172021
Net profit margin
-1142.4%
This company
8.1%
Market median
-14204% vs market
20172021
Asset turnover
0.44×
This company
1.12×
Market median
-61% vs market
20172021
Debt / equity
1.85×
This company
0.62×
Market median
-198% vs market
20172021
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Audit | 2021 | |
SL Liquidator | Liquidator | 2022 |
| Former (1) | ||
PA Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (5) | ||
| Chairman | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2021 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bioimics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sara Camilla Elisabeth Walgeborg | Audit | 0 companies |
| Sara Linnea Elisabet Lööf | Liquidator | 0 companies |
| Per Anders Kalevi Virtanen | Chief Executive Officer | 0 companies |
| Erika Elisabeth Kjellberg Eriksson | Chairman | 0 companies |
| Carl-Erhard Engholm | Board of Directors | 0 companies |
| Jacob Nejtel Kaluski | Board of Directors | 0 companies |
| Angelica Sara Ingrid Loskog | Board of Directors | 0 companies |
| Johan Olof Kämpe | Board of Directors | 0 companies |